Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
15.91
+0.26 (1.66%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
15.91
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 6:19 PM EDT
Takeda Pharmaceutical Company Limited farmatsevtika mahsulotlarini tadqiq qilish, ishlab chiqish, ishlab chiqarish, marketing va litsenziyalash bilan shug'ullanadi. U gastroenterologiya, kam uchraydigan kasalliklar, plazmadan olingan terapiyalar, onkologiya, vaktsinalar va nevrologiya sohalarida farmatsevtika mahsulotlarini taklif etadi. Kompaniya o'z mahsulotlarini Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix va QDENGA brendlari ostida taqdim etadi. U Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology va Nabla Bio bilan mahsulotlarni ishlab chiqish va tijoratlashtirish bo'yicha litsenziyalash va hamkorlikni amalga oshiradi. Kompaniya Yaponiya, Amerika Qo'shma Shtatlari, Yevropa, Kanada, Lotin Amerikasi, Xitoy, Osiyo, Rossiya/Mustaqil Davlatlar Hamdo'stligi, Yaqin Sharq, Okeaniya va Afrikada faoliyat yuritadi. Kompaniya 1781 yilda tashkil etilgan va bosh qarorgohi Yaponiya, Chuo shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Seigo Izumo | Chair of Management Board |
| Michael Fox | Chief Operating Officer |
| Mr. Gabriele Ricci | Chief Data & Technology Officer |
| Mr. Haruhiko Hirate | Member of Management Board |
| Mr. Iwaaki Taniguchi | Senior Vice President of Corporate Finance & Controlling Department |
| Mr. Salvatore Alesci M.D., Ph.D. | Member of Management Board and Head of R&D Global Science & Biomedical Policy |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-26 | 6-K | form6k_062626.htm |
| 2026-06-24 | 6-K | form6k-1_062426.htm |
| 2026-06-17 | IRANNOTICE | iran_notice.htm |
| 2026-06-09 | 6-K | form6k_060926.htm |
| 2026-06-05 | 6-K | form6k_060526.htm |
| 2026-06-01 | 6-K | form6k_060126.htm |
| 2026-05-26 | 6-K | form6k_052626x4.htm |
| 2026-05-22 | SD | formsd_052226.htm |
| 2026-05-19 | 6-K | form6k_051926.htm |
| 2026-05-13 | 6-K | form6k-2_051326.htm |
| Norimasa Takeda | Chief Accounting Officer & Corporate Controller |